Philippe Ledent

Founder at Xpress Biologics SA

Finance

Health Technology

Profile

Mr. Philippe Ledent is a Chief Scientific Officer & Director at Xpress Biologics SA and a Senior Economist at ING Belgium SA/NV.
He is on the Board of Directors at Xpress Biologics SA. He’s responsible for economic scenario and structural research on Belgium and Luxembourg.
Previously, he worked at the Catholic University of Louvain.

Philippe Ledent active positions

Companies	Position	Start
ING Belgium SA/NV ING Belgium SA/NV Investment Banks/BrokersFinance ING Belgium SA/NV is the wholly owned securities broker/dealer subsidiary of ING Groep NV (AMS: INGA) in The Netherlands. Headquartered in Brussels, the firm provides brokerage services to various investors.	Economist	01/01/2008
Xpress Biologics SA Xpress Biologics SA BiotechnologyHealth Technology Xpress Biologics SA develops and produces bio molecules for medical applications. It engages in design of expression systems, process development and manufacturing of new biologics, biosimilars and biobetters, management of the pre-clinical and clinical trials and management of the GMP manufacturing services. The company was founded by Marc Daukandt, Philippe Ledent and Christian Rodriguez on April 14, 2014 and is headquartered in Milmort, Belgium.	Founder	14/04/2014

All active positions of Philippe Ledent

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Philippe Ledent's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
ING Belgium SA/NV ING Belgium SA/NV Investment Banks/BrokersFinance ING Belgium SA/NV is the wholly owned securities broker/dealer subsidiary of ING Groep NV (AMS: INGA) in The Netherlands. Headquartered in Brussels, the firm provides brokerage services to various investors.	Finance
Xpress Biologics SA Xpress Biologics SA BiotechnologyHealth Technology Xpress Biologics SA develops and produces bio molecules for medical applications. It engages in design of expression systems, process development and manufacturing of new biologics, biosimilars and biobetters, management of the pre-clinical and clinical trials and management of the GMP manufacturing services. The company was founded by Marc Daukandt, Philippe Ledent and Christian Rodriguez on April 14, 2014 and is headquartered in Milmort, Belgium.	Health Technology